| 6.49 0.04 (0.62%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.57 | 1-year : | 9.28 |
| Resists | First : | 7.34 | Second : | 7.94 |
| Pivot price | 6.73 |
|||
| Supports | First : | 6.36 | Second : | 5.29 |
| MAs | MA(5) : | 6.51 |
MA(20) : | 6.81 |
| MA(100) : | 8.45 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 22.4 |
D(3) : | 21.5 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 14.68 | Low : | 5.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAGE ] has closed above bottom band by 18.2%. Bollinger Bands are 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.73 - 6.77 | 6.77 - 6.8 |
| Low: | 6.35 - 6.39 | 6.39 - 6.43 |
| Close: | 6.39 - 6.46 | 6.46 - 6.52 |
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Thu, 27 Nov 2025
A Look at Niagen Bioscience (NAGE) Valuation After New Skincare Launch and Long COVID Study Results - Sahm
Thu, 27 Nov 2025
Is Niagen Bioscience Stock Built to Withstand More Downside? - Trefis
Mon, 17 Nov 2025
Niagen Bioscience CFO Pamir Ozan buys shares worth $45,616 - Investing.com
Mon, 17 Nov 2025
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sat, 15 Nov 2025
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years - Seeking Alpha
Tue, 11 Nov 2025
We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 34 (%) |
| Held by Institutions | 41.1 (%) |
| Shares Short | 5,630 (K) |
| Shares Short P.Month | 4,170 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | 16.3 % |
| Operating Margin | 12.4 % |
| Return on Assets (ttm) | 15.6 % |
| Return on Equity (ttm) | 38.9 % |
| Qtrly Rev. Growth | 32.9 % |
| Gross Profit (p.s.) | 0.99 |
| Sales Per Share | 1.56 |
| EBITDA (p.s.) | 0.25 |
| Qtrly Earnings Growth | 150 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 14 (M) |
| PE Ratio | 27.08 |
| PEG Ratio | 0 |
| Price to Book value | 7.38 |
| Price to Sales | 4.15 |
| Price to Cash Flow | 24.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|